High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
about
Current and emerging azole antifungal agentsClinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditionsTreatment of cryptococcosis in the setting of HIV coinfection.Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsLow CD4 count plus coma predicts cryptococcal meningitis in TanzaniaSusceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsResults obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosisDose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.New Insights into HIV/AIDS-Associated Cryptococcosis.The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in KenyaImmune restoration diseases reflect diverse immunopathological mechanisms.HIV in Africa: Challenges and Directions for the Next Decade.Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluidFluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility.High-dose therapy with fluconazole > or = 800 mg day-1.Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.New agents for the treatment of systemic fungal infections--current status.Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.Deciphering the Genic Basis of Yeast Fitness Variation by Simultaneous Forward and Reverse Genetics.The war on cryptococcosis: A Review of the antifungal arsenal.Recommendations for the treatment of established fungal infectionsCryptococcus neoformans meningoencephalitis in a patient with polyarteritis nodosa
P2860
Q24550733-CC8A8423-2A75-473F-8AB2-2C5315F9C475Q28365296-743C430B-B13D-4C5C-8793-2E7E06120218Q30366117-62123144-9D7E-4D99-B822-29CD07B4A9D4Q30435365-E68D6AFF-F3A0-4C54-9A6D-C21E2283C8E5Q30444984-5F7529C1-6B7E-4F09-BE37-DFCD71DD85A6Q33693076-5DC9C411-BB4A-40F2-A1BA-836C6B07D900Q34020746-B195C989-CAA8-439B-8396-925B7A58F34BQ34142328-FBE9BE9F-7AFC-4D0D-9B0F-C2B47411FFE5Q34516548-81A1DD1B-36DD-481D-A0DF-00D6FC9411A1Q34721673-3AC261BC-C497-43C1-A34A-DCB8C01494C9Q34874626-929FBF34-1791-4C64-9AB8-CBA9F62DD3BAQ35628245-F2056EFB-1217-43AA-AFB8-CEB445127DEAQ36364064-9223C1A6-6876-49F6-B89E-AC26E1BDE4A7Q37026726-4AFDFE23-1A5F-43A1-ADAD-2FCAF950256BQ37156556-85BC026C-88D4-4EB0-B8B3-CFF3AB13F749Q37259604-C7FCBB0E-A347-4D4E-BFC5-E72FC2962B46Q37409995-DC808055-399F-4D71-94CF-A3B13426A48BQ38419599-8BD080AC-CD05-45F0-A832-1C1CE0B036A6Q39242940-0B9E0D43-F2EC-411F-921C-644E19E37446Q40600560-C30D33D9-392A-4CE6-9A3E-9750F6F00DC9Q41708431-F443F61F-9071-40A4-BB86-702DDC393217Q41708449-EA0BEFFD-21DE-4213-B742-DDB0392B1D25Q46248271-53E5C001-63DF-40B3-AD6D-E86C3F4C0ED5Q46576615-4E501ADB-E2DB-4B90-8790-EB70F8B08134Q50593909-7DBBD83D-46FF-4C9D-B9D9-3D29B89295DAQ51020220-F10F0213-3B3B-4E32-896D-DD4310B004ECQ54260674-88199189-C328-439C-83DC-989F106031A9Q58207332-83AB0DE2-EEDD-44D0-AE6D-87F80E9D81A7Q58260433-B25841BD-54CF-4DB4-A3CC-858B4DAE895B
P2860
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@en
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@nl
type
label
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@en
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@nl
prefLabel
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@en
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@nl
P2093
P356
P1476
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
@en
P2093
Bassetti D
Bruna Pasticci M
Menichetti F
Miletich F
Pauluzzi S
P304
P356
10.1093/CLINIDS/22.5.838
P407
P577
1996-05-01T00:00:00Z